Alisertib (MLN8237)

Name: Alisertib (MLN8237)
Brand: Selleck Chemicals
SKU: S1133
Rating: 5 (235 reviews)

For research use only.

Catalog No.S1133

235 publications

CAS No. 1028486-01-2

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Alisertib induces cell cycle arrest, apoptosis and autophagy. Phase 3.

Selleck's Alisertib (MLN8237) has been cited by 235 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 574(7777):268-272

PubMed: 31578521 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nat Med, 2016, 22(7):744-53

PubMed: 27213815 ( click the link to review the publication )

Cancer Cell, 2014, 26(3):414-427

PubMed: 25175806 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cancer Commun (Lond), 2021, 10.1002/cac2.12125

PubMed: 33471959 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

J Clin Invest, 2020, 139080

PubMed: 33016928 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Oncogene, 2020, 16

PubMed: 32300176 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2498

PubMed: 32899210 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32235770 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(10):3406-3414

PubMed: 33163279 ( click the link to review the publication )

Mol Cancer Res, 2020, 8

PubMed: 32269073 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.1226.2019

PubMed: 32591441 ( click the link to review the publication )

Front Oncol, 2020, 10:1354

PubMed: 32974133 ( click the link to review the publication )

J Cell Sci, 2020, 133(24)jcs240267

PubMed: 33376154 ( click the link to review the publication )

Dis Model Mech, 2020, dmm.44289

PubMed: 32571902 ( click the link to review the publication )
J Cell Mol Med, 2020, 10.1111/jcmm.15901

PubMed: 32954665 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6690

PubMed: 32932728 ( click the link to review the publication )

Sci Adv, 2020, 6(29):eaba1941

PubMed: 32832623 ( click the link to review the publication )

Cancer Res, 2020, 80(16):3424-3435

PubMed: 32595135 ( click the link to review the publication )

J Cancer, 2020, 11(8):2241-2251

PubMed: 32127951 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:857

PubMed: 33042987 ( click the link to review the publication )

Cancer Lett, 2020, 491:50-59

PubMed: 32735909 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa570

PubMed: 32652013 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3485

PubMed: 31375684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5566

PubMed: 31804482 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2208

PubMed: 31101817 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3430-3442

PubMed: 30755439 ( click the link to review the publication )

Dev Cell, 2019, 50(3):355-366e6

PubMed: 31303441 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Rep, 2019, 26(2):293-301e7

PubMed: 30625311 ( click the link to review the publication )

Oncogene, 2019, 38(1):73-87

PubMed: 30082913 ( click the link to review the publication )

EBioMedicine, 2019, 41:120-133

PubMed: 30799199 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):881

PubMed: 31754113 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):606

PubMed: 31406104 ( click the link to review the publication )
FASEB J, 2019, 33(4):4866-4882

PubMed: 30596512 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003

PubMed: 31257184 ( click the link to review the publication )

Curr Biol, 2019, 29(21):3563-3578

PubMed: 31668617 ( click the link to review the publication )

PLoS Negl Trop Dis, 2019, 13(5):e0007425

PubMed: 31095613 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(3):312-323

PubMed: 30485161 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2211

PubMed: 30778113 ( click the link to review the publication )

Int J Oncol, 2019, 55(4):938-948

PubMed: 31485600 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2019, 41(6):e359-e370

PubMed: 30702467 ( click the link to review the publication )

Target Oncol, 2019, 14(5):563-575

PubMed: 31429028 ( click the link to review the publication )

Oncotarget, 2019, 10(17):1649-1659

PubMed: 30899434 ( click the link to review the publication )

Oncogene, 2019, 38(40):6696-6710

PubMed: 31391550 ( click the link to review the publication )

Blood Adv, 2019, 3(21):3214-3227

PubMed: 31698452 ( click the link to review the publication )

J Vis Exp, 2019, (151)

PubMed: 31589210 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Curr Biol, 2018, 28(21):3458-3468e5

PubMed: 30415701 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6594-6610

PubMed: 30181387 ( click the link to review the publication )

Elife, 2018, doi: 107554/eLife38111

PubMed: 30070631 ( click the link to review the publication )

Thyroid, 2018, doi: 101089/thy20180183

PubMed: 30226440 ( click the link to review the publication )

Oncogene, 2018, 37(33):4599-4610

PubMed: 29755130 ( click the link to review the publication )
Oncogene, 2018, 37(22):2921-2935

PubMed: 29515234 ( click the link to review the publication )

Oncogene, 2018, 37(4):502-511

PubMed: 28967900 ( click the link to review the publication )

BMC Biol, 2018, 16(1):116

PubMed: 30336771 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):781

PubMed: 30013101 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2575-2585

PubMed: 30266802 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

Mol Pharm, 2018, 15(8):3046-3059

PubMed: 29863884 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30544932 ( click the link to review the publication )

Apoptosis, 2018, 23(9-10):492-511

PubMed: 30027525 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):652-668

PubMed: 28749250 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):922

PubMed: 30253737 ( click the link to review the publication )

J Cancer, 2018, 9(12):2061-2071

PubMed: 29937924 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Int J Mol Med, 2018, 41(6):3629-3641

PubMed: 29512701 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):1206-1210

PubMed: 29845253 ( click the link to review the publication )

Anticancer Res, 2018, 38(6):3471-3476

PubMed: 29848699 ( click the link to review the publication )

Oncotarget, 2018, 9(89):35875-35890

PubMed: 30542505 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14017

PubMed: 30228302 ( click the link to review the publication )

Oncotarget, 2018, 9(16):12769-12780

PubMed: 29560108 ( click the link to review the publication )

SLAS Discov, 2018, 23(8):850-861

PubMed: 29742358 ( click the link to review the publication )

J Neurooncol, 2018, 137(3):481-492

PubMed: 29396807 ( click the link to review the publication )
R Soc Open Sci, 2018, 5(12):181303

PubMed: 30662739 ( click the link to review the publication )

Sci Transl Med, 2017, 9(372)

PubMed: 28077684 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8:14294

PubMed: 28220783 ( click the link to review the publication )

Clin Cancer Res, 2017, 10.1158/1078-0432

PubMed: 28073841 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 27593935 ( click the link to review the publication )

EBioMedicine, 2017, 24:43-55

PubMed: 29030058 ( click the link to review the publication )

Plant Physiol, 2017, 173(1):582-599

PubMed: 27879390 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(1):94-107

PubMed: 28848145 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28615297 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2552-2562

PubMed: 28847989 ( click the link to review the publication )

Eur J Med Chem, 2017, 140:1-19

PubMed: 28918096 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(6):670-682

PubMed: 28235899 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

J Cell Sci, 2017, 130(4):683-688

PubMed: 28069833 ( click the link to review the publication )

Cell Discov, 2017, 3:16049

PubMed: 28101375 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

J Biol Chem, 2017, 292(5):1910-1924

PubMed: 28028179 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4652-4672

PubMed: 29118925 ( click the link to review the publication )

Am J Transl Res, 2017, 9(3):845-873

PubMed: 28386317 ( click the link to review the publication )

BMC Cell Biol, 2017, 18(1):33

PubMed: 29141582 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(4):386-401

PubMed: 27396604 ( click the link to review the publication )
Oncotarget, 2017, 8(10):16669-16689

PubMed: 28035071 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(19):32117-32133

PubMed: 28389630 ( click the link to review the publication )

Sci Rep, 2017, 7(1):17978

PubMed: 29269934 ( click the link to review the publication )

Sci Rep, 2017, 7:45514

PubMed: 28358124 ( click the link to review the publication )

Oncotarget, 2017, 8(68):112313-112329

PubMed: 29348827 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19738-19759

PubMed: 28160569 ( click the link to review the publication )

Oncotarget, 2017, 8(41):69691-69708

PubMed: 29050234 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(59):100326-100338

PubMed: 29245981 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114474-114480

PubMed: 29383095 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92926-92942

PubMed: 29190967 ( click the link to review the publication )

Pharmaceuticals (Basel), 2017, 10(3)

PubMed: 29036881 ( click the link to review the publication )

Oncotarget, 2017, 8(31):50376-50392

PubMed: 28881569 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107076-107088

PubMed: 29291012 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Commun, 2016, 7:10180

PubMed: 26782714 ( click the link to review the publication )

Nat Commun, 2016, 7:11389

PubMed: 27091106 ( click the link to review the publication )

Nat Commun, 2016, 7:12674

PubMed: 27624869 ( click the link to review the publication )

Elife, 2016, 5:e11402

PubMed: 26878753 ( click the link to review the publication )

J Med Chem, 2016, 59(15):7188-211

PubMed: 27391133 ( click the link to review the publication )

Arch Toxicol, 2016, 291(10):4939-54

PubMed: 26404763 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2135

PubMed: 26962685 ( click the link to review the publication )
Hum Mol Genet, 2016, 25(8):1574-87

PubMed: 26908596 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(12):3400-3411

PubMed: 27768280 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Cell Biochem, 2016, 117(6):1340-51

PubMed: 26529125 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):566-76

PubMed: 27082306 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):413-24

PubMed: 26713495 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:3473-84

PubMed: 27366084 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 475(3):251-6

PubMed: 27233613 ( click the link to review the publication )

Exp Hematol, 2016, 44(4):247-56

PubMed: 26724640 ( click the link to review the publication )

Mol Med Rep, 2016, 14(1):394-8

PubMed: 27177156 ( click the link to review the publication )

Biol Bull, 2016, 231(1):61-72

PubMed: 27638695 ( click the link to review the publication )

Oncotarget, 2016, 7(22):33152-64

PubMed: 27121204 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84718-84735

PubMed: 27713168 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )

Mol Cancer, 2015, 14(1):83

PubMed: 25889801 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(9):2292-2300

PubMed: 25848977 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):364-72

PubMed: 25395580 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):516-26

PubMed: 25501815 ( click the link to review the publication )

J Cell Sci, 2015, 128(20):3769-80

PubMed: 26349807 ( click the link to review the publication )

J Cell Sci, 2015, 128(3):527-40

PubMed: 25501809 ( click the link to review the publication )
J Cell Sci, 2015, 128(2):364-72

PubMed: ( click the link to review the publication )

Int J Mol Sci, 2015,

PubMed: 26729093 ( click the link to review the publication )

Breast Cancer Res Tr, 2015, 149(3):715-26

PubMed: 25667100 ( click the link to review the publication )

Cell Cycle, 2015, 14(24):3908-19

PubMed: 26697841 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:1555-84

PubMed: 25792811 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:575-601

PubMed: 25632225 ( click the link to review the publication )

BMC Res Notes, 2015, 8:484

PubMed: 26415506 ( click the link to review the publication )

Genes Cancer, 2015, 6(5-6):184-213

PubMed: 26124919 ( click the link to review the publication )

Oncotarget, 2015, 6(34):35247-62

PubMed: 26497213 ( click the link to review the publication )

Clin Cancer Res, 2014, 34(5):2269-74

PubMed: 24778030 ( click the link to review the publication )

Oncogene, 2014, 33(42):4985-96

PubMed: 24166501 ( click the link to review the publication )

Oncogene, 2014, 33(27):3550-60

PubMed: 23955083 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):797-811

PubMed: 25074669 ( click the link to review the publication )

Mol Oncol, 2014, 8(8):1419-28

PubMed: 24953013 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2719-2729

PubMed: 25090971 ( click the link to review the publication )

J Transl Med, 2014, 12(1):200

PubMed: 25082261 ( click the link to review the publication )

Mol Carcinog, 2014, 10.1002/mc.22223

PubMed: 25284017 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

FEBS Lett, 2014, 588(14):2198-205

PubMed: 24857377 ( click the link to review the publication )
Chembiochem, 2014, 15(3):443-50

PubMed: 24403173 ( click the link to review the publication )

PLoS One, 2014, 9(12):e113989

PubMed: 25436453 ( click the link to review the publication )

PLoS One, 2014, 9(3):e92402

PubMed: 24642638 ( click the link to review the publication )

PLoS One, 2014, 9(12):e116048

PubMed: 25545367 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101222

PubMed: 24983972 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

PLoS One, 2014,

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):845-51

PubMed: 25218503 ( click the link to review the publication )

Neurosci Lett, 2014, 583:199-204

PubMed: 25263789 ( click the link to review the publication )

J Pediatr Surg, 2014, 49(1):159-65

PubMed: 24439602 ( click the link to review the publication )

Oncotarget, 2014, 5(10):2947-61

PubMed: 24930769 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6229-42

PubMed: 25153724 ( click the link to review the publication )

Oncotarget, 2014, 5(12):4071-86

PubMed: 24901229 ( click the link to review the publication )

Nat Commun, 2013, 4:2656

PubMed: 24141283 ( click the link to review the publication )

EMBO Mol Med, 2013, 5(1):149-66

PubMed: 23180582 ( click the link to review the publication )

Leukemia, 2013, 27(3):560-8

PubMed: 22940834 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

EMBO Rep, 2013, 14(9):829-36

PubMed: 23887685 ( click the link to review the publication )

Int J Cancer, 2013, 135(3):751-62

PubMed: 24382688 ( click the link to review the publication )

Oral Oncol, 2013, 49(6):551-9

PubMed: 23481312 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(7):1451-9

PubMed: 23597309 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 6):1355-65

PubMed: 23345402 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 9):2102-13

PubMed: 23532825 ( click the link to review the publication )
Biochim Biophys Acta, 2013, 1833(10):2220-32

PubMed: 23707954 ( click the link to review the publication )

Epigenetics Chromatin, 2013, 6(1):21

PubMed: 23829974 ( click the link to review the publication )

J Biol Chem, 2013, 289(1):74-88

PubMed: 24273164 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64306

PubMed: 23717592 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23328114 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27670-81

PubMed: 22753416 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 135(2):433-44

PubMed: 22825030 ( click the link to review the publication )

Cell Cycle, 2012, 11(2):296-309

PubMed: 22214762 ( click the link to review the publication )

Cell Cycle, 2012, 11(13):2567-77

PubMed: 22722494 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30734

PubMed: 22359551 ( click the link to review the publication )

EMBO J, 2011, 30(5):906-19

PubMed: 21297582 ( click the link to review the publication )

Mol Cancer, 2011, 10:131

PubMed: 22011530 ( click the link to review the publication )

Oncotarget, 2011,

PubMed: 21865609 ( click the link to review the publication )

J Cell Biol, 2010, 191(7):1315-32

PubMed: 21187329 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):977-84

PubMed: 21072059 ( click the link to review the publication )

ACS Chem Biol, 2010, 5(6):563-76

PubMed: 20426425 ( click the link to review the publication )

Expert Opin Emerg Dr, 2010, 15(4):615-34

PubMed: 20690888 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Features

First orally available inhibitor of Aurora A.

Targets

Aurora A ^[1]
(Cell-free assay)

1.2 nM

In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. ^[1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. ^[2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT116	MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonDNE42KM7:TR?=	NGDhR\|E4OiCq	MmH2SG1UVw>?	MoTuTWM2OD1yLkC0JO69VQ>?	NEXPR3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
LS174T	NIn3VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFS3Z24xNjVizszN	Mln1O\|IhcA>?	M4LQfmROW09?	Ml7sTWM2OD1yLkC1JO69VQ>?	NEXSfXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
T84	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWqwMlUh\|ryP	MYe3NkBp	MmnySG1UVw>?	NHv0NVNKSzVyPUCuNFkh\|ryP	NIDod2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
LS180	NFrNZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LQTlAvPSEQvF2=	Mn\5O\|IhcA>?	NGHoOndFVVOR	NYHhU49UUUN3ME2xJO69VQ>?	MnvTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
SW948	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPxPHRmOC53IN88US=>	MUO3NkBp	M3KzOmROW09?	M2XMeGlEPTB;MTFOwG0>	NELDbno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlY5PCd-Mk[xN\|Y3QDR:L3G+
HCT15	NVzqNWt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHINE42KM7:TR?=	NF3Pcmo4OiCq	M4nGbGROW09?	NFHKPIFKSzVyPECuOEDPxE1?	NV3jdlA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN\|Y3QDRpPkK2NVM3Pjh2PD;hQi=>
DLD-1	M2fZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUGwMlUh\|ryP	NHz4eWE4OiCq	NHXnUGNFVVOR	M3\KXmlEPTB:MD64JO69VQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nk[4OEc,OjZzM{[2PFQ9N2F-
MIP-101	NWfQOIdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4q3fFAvPSEQvF2=	M3q5VlczKGh?	M2T2OmROW09?	M1PFcWlEPTB;MTFOwG0>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|Nk[4OEc,OjZzM{[2PFQ9N2F-
SNU1544	M1y2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWOwMlUh\|ryP	MV[3NkBp	NWS3boVOTE2VTx?=	MmnuTWM2OD1zIN88US=>	MlPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[2PFQoRjJ4MUO2Olg1RC:jPh?=
OCI-Ly10	MWPDfZRwfG:6aXOgRZN{[Xl?		M2\wUVczKGh?	NGj6cphFVVOR	NF74d5ZKSzVyPUCuNFU5KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
SU-DHL2	NEXJ[VVEgXSxdH;4bYMhSXO\|YYm=		NGTlOWk4OiCq	MWLEUXNQ	MVXJR\|UxRTBwMEGg{txO	NFT5[IE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
OCI-LY7	NX3QTlZmS3m2b4TvfIlkKEG\|c3H5		MVS3NkBp	MomzSG1UVw>?	MX;JR\|UxRTBwMEixJO69VQ>?	M4D5eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
SU-DHL6	MXLDfZRwfG:6aXOgRZN{[Xl?		NWDTWHA1PzJiaB?=	NI\RTHhFVVOR	NX7oW\|Q4UUN3ME2wMlQ5OiEQvF2=	NHvoNXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
Jeko-1	NWrn[phDS3m2b4TvfIlkKEG\|c3H5		M161TVczKGh?	MYnEUXNQ	M3LaSWlEPTB;MD6wNlkh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
JVM-2	MV3DfZRwfG:6aXOgRZN{[Xl?		MoPaO\|IhcA>?	MlTvSG1UVw>?	M4XZUGlEPTB;MD6wNUDPxE1?	Mn:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
Rec-1	NGnFUlVEgXSxdH;4bYMhSXO\|YYm=		M1WzW\|czKGh?	MlfXSG1UVw>?	M4G0VmlEPTB;MD6wPFch\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
Z-138	NIWwblVEgXSxdH;4bYMhSXO\|YYm=		NHnPeWw4OiCq	M3Kzb2ROW09?	MnOzTWM2OD1yLkCxN{DPxE1?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
H9	M4D1[mN6fG:2b4jpZ{BCe3OjeR?=		NFjvfZY4OiCq	NWPMbos6TE2VTx?=	MkD3TWM2OD1yLk[g{txO	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh5OEOzNUc,OjV6N{izN\|E9N2F-
HH	M4X4cWN6fG:2b4jpZ{BCe3OjeR?=		NFvDR3c4OiCq	MoThSG1UVw>?	MXTJR\|UxRTBwNzFOwG0>	NIP5N4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3PFM{OSd-MkW4O\|g{OzF:L3G+
DND41	M1vWb2N6fG:2b4jpZ{BCe3OjeR?=		MVi3NkBp	MlHJSG1UVw>?	MUDJR\|UxRTBwMTFOwG0>	M4fseFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
CCL119	NGjqT4ZEgXSxdH;4bYMhSXO\|YYm=		Ml;wO\|IhcA>?	M3L0bWROW09?	NXHzd5A1UUN3ME2wMlA3OiEQvF2=	MlruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6N{izN\|EoRjJ3OEe4N\|MyRC:jPh?=
J.Cam 1.6	M4LsNGN6fG:2b4jpZ{BCe3OjeR?=		NV3tbXc5PzJiaB?=	MWfEUXNQ	NUXESlgxUUN3ME2wMlExPSEQvF2=	M3rTXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
Sup-T1	NHfx[VlEgXSxdH;4bYMhSXO\|YYm=		NFzKVmM4OiCq	M2C4O2ROW09?	MkTRTWM2OD1{LkG0NkDPxE1?	M3zIelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEe4N\|MyLz5{NUi3PFM{OTxxYU6=
Tib 152	NGWyXpdEgXSxdH;4bYMhSXO\|YYm=		NIi2bG84OiCq	Mmi4SG1UVw>?	M4PZWWlEPTB;MD64JO69VQ>?	NUWzOVdDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4O\|g{OzFpPkK1PFc5OzNzPD;hQi=>
MCF7	M3\xUGZ2dmO2aX;uJGF{e2G7	MX[1JO69VQ>?	MojmNlQhcA>?	NXT1[IFRTE2VTx?=	MV\JcoR2[2W\|IFeyM20h[XK{ZYP0	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	MkHjSpVv[3Srb36gRZN{[Xl?	NIjrcG82KM7:TR?=	MUKyOEBp	NXvBWnBGTE2VTx?=	MnXjTY5lfWOnczDHN{9OKGG{cnXzeC=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MCF7	M4f3eWZ2dmO2aX;uJGF{e2G7	M3K0PVUh\|ryP	NGfsUmUzPCCq	NHvRUYxFVVOR	NEDFU49F\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy	M{n1c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MCF7	M1XtemZ2dmO2aX;uJGF{e2G7	NWD3XFVPPSEQvF2=	NX7ZVmRkOjRiaB?=	MoCwSG1UVw>?	M4mzc2Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz	M4DUcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MCF7	NUX0PIRmTnWwY4Tpc44hSXO\|YYm=	M4PTcFUh\|ryP	NIjoZ3EzPCCq	M{S2dmROW09?	MkTVSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?=	NV7G[oh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	MmjRSpVv[3Srb36gRZN{[Xl?	MnXYOUDPxE1?	MUmyOEBp	M1S4NWROW09?	MXjJcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=>	NGnyOG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MCF7	M1\5S2Z2dmO2aX;uJGF{e2G7	M3jIXFUh\|ryP	M4jEPVI1KGh?	MYnEUXNQ	NHPUN3VKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG=	NFjtVGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MDA-MB-231	M136VmZ2dmO2aX;uJGF{e2G7	M1v4PFUh\|ryP	NX;USIt3OjRiaB?=	NFTSZ2dFVVOR	NVW2e254TGWlcnXhd4V{KHSqZTDlfJBz\XO\|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=>	MkXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MDA-MB-231	NGr5XXpHfW6ldHnvckBCe3OjeR?=	Mon4NUDPxE1?	MVKyOEBp	MknGSG1UVw>?	M3HtZmlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	M4rBbGZ2dmO2aX;uJGF{e2G7	MnvsOUDPxE1?	MWOyOEBp	NHryRotFVVOR	MnrySIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	MVjGeY5kfGmxbjDBd5NigQ>?	MYG1JO69VQ>?	NHvsXlIzPCCq	MlPuSG1UVw>?	MmPVTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE>	M373S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAyLz5{NUizOFQxOTxxYU6=
MDA-MB-231	MUDGeY5kfGmxbjDBd5NigQ>?	MYK1JO69VQ>?	MVyyOEBp	MXzEUXNQ	NInNbHNKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NESwNUc,OjV6M{S0NFE9N2F-
MDA-MB-231	NHzZWlRHfW6ldHnvckBCe3OjeR?=	NFvwTYE2KM7:TR?=	NHHHWYszPCCq	NUGxU4tDTE2VTx?=	M1TmXWlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDwOVM>	MmGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
MCF7	M1ntXmFxd3C2b4Ppd{BCe3OjeR?=	MknMOUDPxE1?	NV\xXJlmOjRiaB?=	M3;VcmROW09?	MmXtTY5lfWOnczDhdI9xfG:2aXOg[IVifGh?	NYnTW3ZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MDA-MB-231	NILDRW5CeG:ydH;zbZMhSXO\|YYm=	NGj2U\|Q2KM7:TR?=	M2XKOVI1KGh?	NI[5fodFVVOR	NFzXTXRKdmS3Y3XzJIFxd3C2b4TpZ{Bl\WG2aB?=	NYrYWHoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q1ODFpPkK1PFM1PDBzPD;hQi=>
MCF7	M1rWTGZ2dmO2aX;uJGF{e2G7	NGfK[HoyKM7:TR?=	MkL0O\|IhcA>?	MWHEUXNQ	NH;MXHJKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi=	NHzZWIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOSd-MkW4N\|Q1ODF:L3G+
MDA-MB-231	MmnkSpVv[3Srb36gRZN{[Xl?	Mnu2NUDPxE1?	M3PJflczKGh?	MYTEUXNQ	NWrNSo5wUW6mdXPld{BifXSxcHjh[4lkKGSnYYTo	MoHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{S0NFEoRjJ3OEO0OFAyRC:jPh?=
U-2 OS	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXi1NEDPxE1?	NX3OUWZrOjRiaB?=	M1e0NWROW09?	Mn\LTWM2OD1zNj62JO69VQ>?	MkXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUK4NVEoRjJ3N{myPFEyRC:jPh?=
MG-63	NGf5[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVW1NEDPxE1?	M4XoTlI1KGh?	MWHEUXNQ	MWnJR\|UxRTlwNTFOwG0>	M2D3RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{myPFEyLz5{NUe5NlgyOTxxYU6=
U-2 OS	MWHBdI9xfG:\|aYOgRZN{[Xl?	MkHLOUDPxE1?	M4LQT\|I1KGh?	NXXFTlA4TE2VTx?=	MV\JcoR2[2W\|IHHwc5B1d3SrYzDj[YxtKGSnYYTo	NWWxbZE5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVI5OTFpPkK1O\|kzQDFzPD;hQi=>
MG-63	MmjaRZBweHSxc3nzJGF{e2G7	NV24[mRQPSEQvF2=	NVTK[XhwOjRiaB?=	Mln2SG1UVw>?	MYjJcoR2[2W\|IHHwc5B1d3SrYzDj[YxtKGSnYYTo	NHi2TYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NlgyOSd-MkW3PVI5OTF:L3G+
U-2 OS	MWjGeY5kfGmxbjDBd5NigQ>?	MmjmOUDPxE1?	Mn3VNlQhcA>?	MYnEUXNQ	M{\v[XBzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>?	NXvnTIVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVI5OTFpPkK1O\|kzQDFzPD;hQi=>
MG-63	M{HNb2Z2dmO2aX;uJGF{e2G7	NInQb\|U2KM7:TR?=	MlnRNlQhcA>?	NIrRNmNFVVOR	Ml3XVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp	M1TIdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{myPFEyLz5{NUe5NlgyOTxxYU6=
PANC-1	M4TyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLSWJgxPTBizszN	NVHXT4VuOjRiaB?=	NUTFSGpzTE2VTx?=	M3vLXWlEPTB;Nz6xJO69VQ>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|MkKyOUc,OjV4M{KyNlU9N2F-
BxPC-3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\3OVAh\|ryP	M1jseFI1KGh?	NGDRO2ZFVVOR	M{HaNGlEPTB;Nj64JO69VQ>?	NFqwR\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzPSd-MkW2N\|IzOjV:L3G+
PANC-1	NUPyS3pzTnWwY4Tpc44hSXO\|YYm=	MkXDOUDPxE1?	NHTtOW4zPCCq	MV3EUXNQ	M2Sx[mlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>?	NF7ZTo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzPSd-MkW2N\|IzOjV:L3G+
BxPC-3	NWXFNHZqTnWwY4Tpc44hSXO\|YYm=	M2fwT\|Uh\|ryP	NXX6UoJlOjRiaB?=	NV\BbnFvTE2VTx?=	MX3JcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U>	NIPQbpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzPSd-MkW2N\|IzOjV:L3G+
PANC-1	NEjseJFHfW6ldHnvckBCe3OjeR?=	NULZSVFTPSEQvF2=	MYWyOEBp	NVzuPZc3TE2VTx?=	NWCxOVBZUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh?	NIK2eWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzPSd-MkW2N\|IzOjV:L3G+
BxPC-3	NU\Ed2h{TnWwY4Tpc44hSXO\|YYm=	NHjwblU2KM7:TR?=	NYXqeWhNOjRiaB?=	NEXBOlBFVVOR	MXLJcoR2[2W\|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=>	NXPIRXRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjVpPkK1OlMzOjJ3PD;hQi=>
SKOV3	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXQNVAxKM7:TR?=	MkG5NlQhcA>?	NYHpXItUTE2VTx?=	M{n2UWlEPTB;MkCuOFgh\|ryP	M4\kSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK0O\|UxLz5{NU[yOFc2ODxxYU6=
OVCAR4	NYDUVI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXyxTXpSOTByIN88US=>	NEPFbHEzPCCq	MnLtSG1UVw>?	MVXJR\|UxRTJ{LkGzJO69VQ>?	M37ybVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK0O\|UxLz5{NU[yOFc2ODxxYU6=
SKOV3	NGX3XmRHfW6ldHnvckBCe3OjeR?=	NGLG[Ho2KM7:TR?=	M3HPclczKGh?	M{nSZmROW09?	NVG5U4VIUW6mdXPld{BIOi:PIHHydoV{fA>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
OVCAR4	MYnGeY5kfGmxbjDBd5NigQ>?	MWO1JO69VQ>?	MnO2O\|IhcA>?	M2TDXmROW09?	MnzpTY5lfWOnczDHNk9OKGG{cnXzeC=>	NV3CUVZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlQ4PTBpPkK1OlI1PzVyPD;hQi=>
SKOV3	MVnBdI9xfG:\|aYOgRZN{[Xl?	NFjRVpQ2KM7:TR?=	NHW1VZUzPCCq	NELDdIlFVVOR	NHPIOYFKdmS3Y3XzJIFxd3C2b4Ppdy=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NEe1NEc,OjV4MkS3OVA9N2F-
OVCAR4	MnLtRZBweHSxc3nzJGF{e2G7	NFHJdIE2KM7:TR?=	NIfCfHYzPCCq	MVfEUXNQ	M3KzWGlv\HWlZYOgZZBweHSxc3nz	NGf0bmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOFc2OCd-MkW2NlQ4PTB:L3G+
AGS	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWeyOUDPxE1?	M{\FR\|I1KGh?	MlHXSG1UVw>?	MnPWTWM2OD1zOT6wPUDPxE1?	M1:0TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkC5PVI{Lz5{NU[wPVkzOzxxYU6=
NCI-N78	NVHBTGVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn30NlUh\|ryP	MmXyNlQhcA>?	NWOxeJB3TE2VTx?=	Mk[yTWM2OD1{Nj6zN{DPxE1?	NFz3NoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[wPVkzOyd-MkW2NFk6OjN:L3G+
AGS	NWPxU3NuSXCxcITvd4l{KEG\|c3H5	NFK2XIs2KM7:TR?=	NXu2TZhDOjRiaB?=	NXvQfoliTE2VTx?=	M3jWbGlv\HWlZYOgZZBweHSxc3nz	M{PWZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkC5PVI{Lz5{NU[wPVkzOzxxYU6=
NCI-N78	M4WxWWFxd3C2b4Ppd{BCe3OjeR?=	MUO1JO69VQ>?	NWf0TG42OjRiaB?=	MXPEUXNQ	M2nP[Wlv\HWlZYOgZZBweHSxc3nz	M{LmdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkC5PVI{Lz5{NU[wPVkzOzxxYU6=
AGS	M1XxVmZ2dmO2aX;uJGF{e2G7	MoDkOUDPxE1?	M3TMclI1KGh?	M1XDcmROW09?	MYXJcoR2[2W\|IITo[UBifXSxcHjh[5k>	NXXMbJg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NFk6OjNpPkK1OlA6QTJ\|PD;hQi=>
NCI-N78	MVrGeY5kfGmxbjDBd5NigQ>?	MlXVOUDPxE1?	NXnuXoY3OjRiaB?=	M1TFbmROW09?	NYDsbINDUW6mdXPld{B1cGViYYX0c5Bp[We7	Mkj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MEm5NlMoRjJ3NkC5PVI{RC:jPh?=
HSC-3	MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYi5WGVXOSEQvF2=	MUe0PEBp		MX\JR\|UxRTBwNUSg{txO	M4jBNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{[2NVQ{Lz5{NUO2OlE1OzxxYU6=
GB30	NX;NS2tET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\IRVEh\|ryP	MnH6O{Bl	MUTEUXNQ	MUXJR\|UxRTBwMEGxJO69VQ>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyNkSyPEc,OjVzME[0Nlg9N2F-
GB9	NWi3O2NoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVuxJO69VQ>?	MXO3JIQ>	NYPXdFltTE2VTx?=	MULJR\|UxRTBwMEK0JO69VQ>?	MoX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzME[0NlgoRjJ3MUC2OFI5RC:jPh?=
GB169	NEDpfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXi5V2JlOSEQvF2=	NGHR[oQ4KGR?	NXPEZmVWTE2VTx?=	MmLxTWM2OD1yLkCzNkDPxE1?	M4HyZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC2OFI5Lz5{NUGwOlQzQDxxYU6=
T24	NUjuZ4doTnWwY4Tpc44hSXO\|YYm=	MVuxJO69VQ>?	NV7NTok5PDhiaB?=	MWPEUXNQ	NFLDVmpKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0	NIDVc4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN\|Y{Oyd-MkO0NFM3OzN:L3G+
RT4	NFfqV2hHfW6ldHnvckBCe3OjeR?=	NWjpO2tCOSEQvF2=	MnjpOFghcA>?	MmPNSG1UVw>?	NWP2d29iUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=>	M3fjSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NECzOlM{Lz5{M{SwN\|Y{OzxxYU6=
UM-UC-3	MofBSpVv[3Srb36gRZN{[Xl?	MXSxJO69VQ>?	MVy0PEBp	MYLEUXNQ	MknwTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dB?=	NV\CTVBXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzNpPkKzOFA{PjN\|PD;hQi=>
T24	NIi5bIlCeG:ydH;zbZMhSXO\|YYm=	NGq3bmY{NjF4IN88US=>	M3TTbVk3KGh?	MX;EUXNQ	M3O1N2lEPTB;MD6wN\|A3KM7:TR?=	NIXLPIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN\|Y{Oyd-MkO0NFM3OzN:L3G+
RT4	MWnBdI9xfG:\|aYOgRZN{[Xl?	MVmzMlE3KM7:TR?=	NFTzboY6PiCq	M3v6PGROW09?	MlXBTWM2OD1yLkGxPVgh\|ryP	NUDvVVI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzNpPkKzOFA{PjN\|PD;hQi=>
UM-UC-3	NH;nfIZCeG:ydH;zbZMhSXO\|YYm=	MlnQN{4yPiEQvF2=	M2r2Z\|k3KGh?	NFi0SVZFVVOR	M32wcGlEPTB;MD6wOFQ6KM7:TR?=	NWi0S4Z6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFM3OzNpPkKzOFA{PjN\|PD;hQi=>
OVCAR-5	M1PGbGZ2dmO2aX;uJGF{e2G7	NYW0eoszPTBibl2=			MYrJcohq[mm2czDj[YxtKG2rZ4LheIlwdg>?	NV\KPYcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzN\|Q{OjdpPkKzN\|M1OzJ5PD;hQi=>
SKOV3ip2	Mm\oSpVv[3Srb36gRZN{[Xl?	Ml\hOVAhdk1?			M1WzT2lvcGmkaYTzJINmdGxibXnndoF1cW:w	M2SyelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{O0N\|I4Lz5{M{OzOFMzPzxxYU6=
S462	M{jmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HoU\|ExOCEQvF2=	M3HsWlczKGh?	MVrEUXNQ	MoTsRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>?	NEO0O5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFEyPCd-MkOzNlgyOTR:L3G+
2884	M{XWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYixNFAh\|ryP	M2fOTlczKGh?	NYq0WWg5TE2VTx?=	M1W5O2F1fGWwdXH0[ZMh[2WubDDndo94fGh?	NFvHPYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFEyPCd-MkOzNlgyOTR:L3G+
2885	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWOxNFAh\|ryP	NYToVXZ6PzJiaB?=	MofISG1UVw>?	NXnMV\|FwSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?=	NUTBfGZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNlgyOTRpPkKzN\|I5OTF2PD;hQi=>
CRL-2396	NGXrWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXixNFAh\|ryP		MVj3ZZRmeg>?	MWDJR\|UxRTBwMEmyJO69VQ>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF3M{WyOEc,OjNzNUO1NlQ9N2F-
TIB-48	NI[1O5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzCNVAxKM7:TR?=		NHjXenl4[XSnch?=	M1X1R2lEPTB;MD6wPFgh\|ryP	MorNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzNUO1NlQoRjJ\|MUWzOVI1RC:jPh?=
CRL-2396	NHK5OJdEgXSxdH;4bYMhSXO\|YYm=	MWqxJO69VQ>?	NHPmS4s1QCCq	NF7v[ZZ4[XSnch?=	MUDJcoR2[2W\|IHHwc5B1d3Orcx?=	NYPIW4xzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxOVM2OjRpPkKzNVU{PTJ2PD;hQi=>
TIB-48	M4DtTmN6fG:2b4jpZ{BCe3OjeR?=	NYrQZ25oOSEQvF2=	NUPpflBCPDhiaB?=	MU\3ZZRmeg>?	NGr0V\|JKdmS3Y3XzJIFxd3C2b4Ppdy=>	NHPydXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G1N\|UzPCd-MkOxOVM2OjR:L3G+
AGS	Mly1R5l1d3SxeHnjJGF{e2G7	NYr3eIJ2OC53IN88US=>	NVH0SJo3OjRiaB?=	MlyzSG1UVw>?	NXrnV2NjTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy=	M1fnVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUeyOlEyLz5{Mkm3NlYyOTxxYU6=
FLO-1	M1voRWN6fG:2b4jpZ{BCe3OjeR?=	MXiwMlUh\|ryP	M4nid\|I1KGh?	NYXjTWkyTE2VTx?=	MXnE[YNz\WG\|ZYOgZ4VtdCC\|dYL2bZZidA>?	M2LxTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUeyOlEyLz5{Mkm3NlYyOTxxYU6=
OE33	MnzaR5l1d3SxeHnjJGF{e2G7	NWLRR3h{OC53IN88US=>	NH;pU4czPCCq	MXPEUXNQ	NELLXZRF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?=	NUfHNWFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5O\|I3OTFpPkKyPVczPjFzPD;hQi=>
SKLMS	MVTDfZRwfG:6aXOgRZN{[Xl?	MoXqO\|Uhdk1?	M{fSZlk3KGh?		MV\JcoR2[2W\|IHHwc5B1d3Orcx?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{MUm5O{c,OjJ6MkG5PVc9N2F-
Leio285	M2HE[mN6fG:2b4jpZ{BCe3OjeR?=	M3\Hc\|c2KG6P	NXu1bll5QTZiaB?=		NFjVW4FKdmS3Y3XzJIFxd3C2b4Ppdy=>	M1f3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEKxPVk4Lz5{MkiyNVk6PzxxYU6=
Mes-Sa	NFryVm1EgXSxdH;4bYMhSXO\|YYm=	MYe3OUBvVQ>?	NHflTnI6PiCq		NFzhN5pKdmS3Y3XzJIFxd3C2b4Ppdy=>	NGq0U449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyNVk6Pyd-MkK4NlE6QTd:L3G+
DAOY	MkHDR5l1d3SxeHnjJGF{e2G7	NWKzZ3JpOTBizszN	NUfGbnNoPzJiaB?=	MWfEUXNQ	NVnJfJRIUUN3ME2wMlA1KM7:TR?=	M3HUR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nk[5N\|M2Lz5{Mk[2PVM{PTxxYU6=
IMR32	MWTDfZRwfG:6aXOgRZN{[Xl?	MWexNEDPxE1?	MYe3NkBp	NUjhUZVITE2VTx?=	MUjJR\|UxRTBwMEOg{txO	M2rlclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{Nk[5N\|M2Lz5{Mk[2PVM{PTxxYU6=
Molt-4	M3LGTGN6fG:2b4jpZ{BCe3OjeR?=	NGmyTFYyOCEQvF2=	M4\KZ\|czKGh?	NVPCUYxRTE2VTx?=	NVHBUWFuUUN3ME2wMlAzKM7:TR?=	NFzDdnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[2PVM{PSd-MkK2Olk{OzV:L3G+
MOLM-13	Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{naNFMh\|ryP	NXfP[IIzPzJiaB?=		M1jodGRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	NUXPfFFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFgzPDlpPkKyOFg5OjR7PD;hQi=>
HL-60	NVG3RpFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFiyOnk{KM7:TR?=	M{m3S\|czKGh?		NV\WZW4zTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	NGDkO\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
MV4-11	M{G5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7ieVk{KM7:TR?=	MXy3NkBp		MYnEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR6OEK0PUc,OjJ2OEiyOFk9N2F-
SKM-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HxOVMh\|ryP	NX7CeYN{PzJiaB?=		MXHEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	M1vKO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEi4NlQ6Lz5{MkS4PFI1QTxxYU6=
SH2	M4ftU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXuzJO69VQ>?	M4WzO\|czKGh?		Mn\vSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?=	M3nyc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEi4NlQ6Lz5{MkS4PFI1QTxxYU6=
NOMO-1	M2S1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\1VYc{KM7:TR?=	MVe3NkBp		M2XWbWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm=	NGLDPYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4PFI1QSd-MkK0PFgzPDl:L3G+
OCL-AML2	M1S3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fKUVMh\|ryP	NHTLZlc4OiCq		MmjlSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?=	MkHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OEiyOFkoRjJ{NEi4NlQ6RC:jPh?=
PL-21	M{i5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLUTIM{KM7:TR?=	NUH4[2VpPzJiaB?=		NWjacFhbTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=>	M2rnd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEi4NlQ6Lz5{MkS4PFI1QTxxYU6=
KG-1	M3TmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYGzJO69VQ>?	MoL4O\|IhcA>?		MXzEbY1qdmm\|aHXzJINmdGxidnnhZoltcXS7	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR6OEK0PUc,OjJ2OEiyOFk9N2F-
A172	M1LKZmN6fG:2b4jpZ{BCe3OjeR?=	NH\XNm8yODBizszN	NWXpV4JqOjRiaB?=	NGLidYpFVVOR	NUTyT3FsUUN3ME2wMlEzOCEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
U87	NGXRbXFEgXSxdH;4bYMhSXO\|YYm=	NXP5dWp5OTByIN88US=>	M320NFI1KGh?	M4LhW2ROW09?	NH\4cJNKSzVyPUCuNVA2KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
U251	NIOzcG5EgXSxdH;4bYMhSXO\|YYm=	M1GwSVExOCEQvF2=	NVnEfY9rOjRiaB?=	MkTKSG1UVw>?	MVXJR\|UxRTBwMUCwJO69VQ>?	NHHkfpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
T98	NHLCb\|lEgXSxdH;4bYMhSXO\|YYm=	NE\ybm8yODBizszN	MnvtNlQhcA>?	MVnEUXNQ	M{nXS2lEPTB;MD6xNlUh\|ryP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
LN18	NHnKSllEgXSxdH;4bYMhSXO\|YYm=	Mn7lNVAxKM7:TR?=	MVWyOEBp	Ml[ySG1UVw>?	NHT5Z5NKSzVyPUCuNlExKM7:TR?=	NUPuWWVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyO\|Q{QTlpPkKyNlc1Ozl7PD;hQi=>
LN443	M1\Fc2N6fG:2b4jpZ{BCe3OjeR?=	NEfXeHcyODBizszN	MorrNlQhcA>?	M4fmR2ROW09?	NWD4fZYyUUN3ME2wMlIzOCEQvF2=	MoPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
HF66	NVPRVlNCS3m2b4TvfIlkKEG\|c3H5	MWWxNFAh\|ryP	Ml;oNlQhcA>?	MXjEUXNQ	MoXNTWM2OD1yLkKyOUDPxE1?	MnPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
HF2303	M1PjNGN6fG:2b4jpZ{BCe3OjeR?=	MUKxNFAh\|ryP	MV2yOEBp	Moj5SG1UVw>?	NVnKOnF5UUN3ME2wMlA3OCEQvF2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ5NEO5PUc,OjJ{N{SzPVk9N2F-
HF2359	MX3DfZRwfG:6aXOgRZN{[Xl?	NXXNdmxGOTByIN88US=>	M3jZU\|I1KGh?	MYfEUXNQ	NITTNYtKSzVyPUCuNFYxKM7:TR?=	NGfZb3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3OFM6QSd-MkKyO\|Q{QTl:L3G+
HF2414	M2TBNGN6fG:2b4jpZ{BCe3OjeR?=	M3L6PFExOCEQvF2=	M{DENlI1KGh?	MmfySG1UVw>?	NWfEfII1UUN3ME2wMlA5OCEQvF2=	MnPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{SzPVkoRjJ{Mke0N\|k6RC:jPh?=
A-673	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NES2N4wyOCEQvF2=	MUS5OkBp	NWrpb2Z[TE2VTx?=	M2\MUmlEPTB;MD6wN\|Ih\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
TC-32	Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nGR\|ExKM7:TR?=	MVy5OkBp	NXrNTWU5TE2VTx?=	NWDueVJSUUN3ME2wMlA{QSEQvF2=	NYm5VlNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
TC-71	MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TmO\|ExKM7:TR?=	MmraPVYhcA>?	NH;tV3NFVVOR	MWLJR\|UxRTBwMUCyJO69VQ>?	M{LXN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SK-N-MC	Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfCNVAh\|ryP	MUS5OkBp	NFmwdYpFVVOR	NVXhWWoyUUN3ME2wMlA4OiEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-9	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX[xNEDPxE1?	MWK5OkBp	MofLSG1UVw>?	NGfrdWtKSzVyPUCuNFE5KM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-10	NXWwWmhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUexNEDPxE1?	NFfXXGw6PiCq	NIPaXJBFVVOR	NGL1XlhKSzVyPUCuNFYxKM7:TR?=	M4nCRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
CHLA-25	NX;oT5BRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHXVVIyOCEQvF2=	MWq5OkBp	M3v2TWROW09?	M3PCfGlEPTB;MD6xOlgh\|ryP	Mn\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
CHLA-32	NH3rW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVexNEDPxE1?	NX\DOoNDQTZiaB?=	MWjEUXNQ	MoLKTWM2OD1yLkGzOkDPxE1?	NGDsXHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-56	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjBNVAh\|ryP	MV25OkBp	MlHJSG1UVw>?	MXrJR\|UxRTFyIN88US=>	NHTYXZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-258	MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HyZ\|ExKM7:TR?=	MWq5OkBp	MUXEUXNQ	M2HPdmlEPTB;MD6xN\|Ih\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
COG-E-352	M2DWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTofm4yOCEQvF2=	M2fNeVk3KGh?	MUPEUXNQ	NV7vb402UUN3ME2wMlA1OyEQvF2=	NGTYSY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-90	M2XVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXqxNEDPxE1?	NWW1SpE5QTZiaB?=	MmXjSG1UVw>?	NUXzTYtCUUN3ME2wMlA3OSEQvF2=	M2LoNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
CHLA-119	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUWxNEDPxE1?	NYPidmZmQTZiaB?=	NHG3blhFVVOR	M3Wy[GlEPTB;MD6wNlIh\|ryP	NH;F[4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
CHLA-122	NWG0SmU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXONVAh\|ryP	M2L6dlk3KGh?	NVXqdHpSTE2VTx?=	Moe0TWM2OD1yLkCxPUDPxE1?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-136	M4[yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWOxNEDPxE1?	MnPNPVYhcA>?	MWDEUXNQ	NEfKN\|RKSzVyPUCuNFM6KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
CHLA-140	M2nyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUexNEDPxE1?	NV\BZnRGQTZiaB?=	M1XENWROW09?	MUPJR\|UxRTBwMEK2JO69VQ>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
LA-N-6	Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\zWFExKM7:TR?=	MXG5OkBp	MlXISG1UVw>?	MnH0TWM2OD1yLkC1OEDPxE1?	NIjaWVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
NB-1643	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorCNVAh\|ryP	NVXXfWRxQTZiaB?=	MkL3SG1UVw>?	NXLlUHp3UUN3ME2wMlA{PyEQvF2=	M1LK[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
NB-EBc1	M1GzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrTNVAh\|ryP	M1q1[Vk3KGh?	NWHTV4JJTE2VTx?=	NHfsSHRKSzVyPUCuNFUxKM7:TR?=	Ml\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
SK-N-BE-1	NFrQNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX2xNEDPxE1?	NHnYPGE6PiCq	M4DN[mROW09?	M1npXGlEPTB;MD6wNlgh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR2OEW5NUc,OjF2NEi1PVE9N2F-
SK-N-BE-2	NHT2[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4j1U\|ExKM7:TR?=	MX:5OkBp	NF;hOWNFVVOR	MmKzTWM2OD1yLkCzOkDPxE1?	NUHhXVRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-KAN	NGLL[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLmNVAh\|ryP	NG\Tbog6PiCq	NE[1d\|dFVVOR	MoLOTWM2OD1yLkCzOEDPxE1?	NV;OU2ZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-KANR	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW[xNEDPxE1?	MkTyPVYhcA>?	MXLEUXNQ	M4\OS2lEPTB;MD6wNlYh\|ryP	M1TXdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNES4OVkyLz5{MUS0PFU6OTxxYU6=
SMS-KCN	M{nHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PlOVExKM7:TR?=	MoXHPVYhcA>?	MV;EUXNQ	MYDJR\|UxRTBwMEG5JO69VQ>?	NGLQ[G09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-KCNR	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jRTlExKM7:TR?=	MYK5OkBp	NVGwbJp1TE2VTx?=	M1HXNmlEPTB;MD6wNVAh\|ryP	NWXRVIdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OFg2QTFpPkKxOFQ5PTlzPD;hQi=>
SMS-LHN	NVXEXnNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\JWmZLOTBizszN	MVW5OkBp	MXTEUXNQ	MVXJR\|UxRTBwMEOyJO69VQ>?	Mkn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
SMS-MSN	NF\4coRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYqxNEDPxE1?	MlG2PVYhcA>?	NFfvOJVFVVOR	NF;4T3pKSzVyPUCuNFIzKM7:TR?=	NEOzTZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS0PFU6OSd-MkG0OFg2QTF:L3G+
SMS-SAN	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzGSmZkOTBizszN	NX2zcGNiQTZiaB?=	NEOxeZlFVVOR	NXnidYs1UUN3ME2wMlAzOCEQvF2=	MkPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NEi1PVEoRjJzNES4OVkyRC:jPh?=
Granta-4	MlXUR5l1d3SxeHnjJGF{e2G7	MnXHNVAh\|ryP	M1fwV\|ch\A>?		NYi0[\|FYUUN3ME2wMlA1OCEQvF2=	NVHsXnVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVE5PjdpPkKxNlkyQDZ5PD;hQi=>
DB	NUX4[IxIS3m2b4TvfIlkKEG\|c3H5	MW[xNEDPxE1?	MmLiO{Bl		Mm\CTWM2OD1yLkC0NkDPxE1?	NU[yV3BNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVE5PjdpPkKxNlkyQDZ5PD;hQi=>
RL	MkDPR5l1d3SxeHnjJGF{e2G7	Mn3FNVAh\|ryP	MXq3JIQ>		MkfHTWM2OD1yLkCxOUDPxE1?	NY\oV5k4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVE5PjdpPkKxNlkyQDZ5PD;hQi=>
K562	NVvFOGVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXSxNEDPxE1?	MVW5OkBp		M4LNc2lEPTB;MD6wPFch\|ryP	NWfQd2o{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPVE3OzNpPkKxNFkyPjN\|PD;hQi=>
LAMA-84	MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHrNVAh\|ryP	NU\KbXM2QTZiaB?=		MkfHTWM2OD1yLkC1O{DPxE1?	MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyOUG2N\|MoRjJzMEmxOlM{RC:jPh?=
MM15	M1q3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1ezeFQh\|ryP	NVXDOo53PzJiaB?=	NU\6bG1STE2VTx?=	MVLJR\|UxRTBwMUOg{txO	M1PGOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
OPM1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoH0OEDPxE1?	MmntO\|IhcA>?	MUPEUXNQ	M3XWO2lEPTB;MD6wN{DPxE1?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN6Mki0OEc,OjB\|OEK4OFQ9N2F-
RPM1	NFPJSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LC[VQh\|ryP	MYK3NkBp	M13OUGROW09?	NXXGTlhPUUN3ME2xNE4{OiEQvF2=	M{DiNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
INA6	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofCOEDPxE1?	NEDFTVI4OiCq	M4rybWROW09?	NFu0S5JKSzVyPUCuNFAzKM7:TR?=	M1rSWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
OPM2	M{WzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWK1fVlxPCEQvF2=	MlrmO\|IhcA>?	MXPEUXNQ	MoL4TWM2OD12LkO3JO69VQ>?	NF7zZo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO4Nlg1PCd-MkCzPFI5PDR:L3G+
MM1R	NVvtOWNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU[0JO69VQ>?	NITlb2E4OiCq	M{iybWROW09?	M3q2XWlEPTB;MT62PEDPxE1?	NXPDN2ljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPFI5PDRpPkKwN\|gzQDR2PD;hQi=>
DOX40	M3XU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnhb3h1PCEQvF2=	NFX4XG44OiCq	NITycndFVVOR	MXTJR\|UxRTVwNEig{txO	MmfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEK4OFQoRjJyM{iyPFQ1RC:jPh?=
LR5	NYXXUGxUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3SOZk1KM7:TR?=	NEfvNJc4OiCq	NYTOOVRwTE2VTx?=	NHTQZWVKSzVyPUKuOVMh\|ryP	M2nwNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
U266	MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2H6UFQh\|ryP	MlzoO\|IhcA>?	NWK3eWt{TE2VTx?=	MV;JR\|UxRTFwNEOg{txO	M4i2WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{iyPFQ1Lz5{MEO4Nlg1PDxxYU6=
RD	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGD4OVEyOCEQvF2=	MnXPPVYhcA>?		NXjWNm9LUUN3ME2wMlIzQCEQvF2=	NYm0[ZZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
Rh41	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jPNFExKM7:TR?=	MXy5OkBp		MkPVTWM2OD1yLkC5NEDPxE1?	NYrnToc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
Rh30	M2\Q[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjuNVAh\|ryP	MUm5OkBp		MXvJR\|UxRTBwMkOwJO69VQ>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
BT-12	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zU[VExKM7:TR?=	M1PWNVk3KGh?		MnfrTWM2OD1yLkC2NEDPxE1?	NVG4Zm5XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
CHLA-266	M2nxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TueVExKM7:TR?=	M1rTfFk3KGh?		M1zNcGlEPTB;MD6wO\|Ih\|ryP	NV3aOYRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
TC-71	Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVSxNEDPxE1?	NXLI[WJpQTZiaB?=		MWfJR\|UxRTBwMUCyJO69VQ>?	MnfnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
SJ-GBM2	NIP3doFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPhNVAh\|ryP	NVztd4RQQTZiaB?=		MWPJR\|UxRTBwMEWwJO69VQ>?	MkfBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
NALM-6	NWHYXHNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\YW2QxOTBizszN	MnTyPVYhcA>?		MVLJR\|UxRTBwME[yJO69VQ>?	NWjWWFJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
COG-LL-317	Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWKxNEDPxE1?	M{W0XVk3KGh?		M{jVNWlEPTB;MD6wOFch\|ryP	MnfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzMEizN\|goRjJyMUC4N\|M5RC:jPh?=
RS4-11	MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX:xNEDPxE1?	MlTBPVYhcA>?		NIrTV2xKSzVyPUCuNFE5KM7:TR?=	M4C4b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
MOLT-4	NH3oepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY[xNEDPxE1?	MlvpPVYhcA>?		M3\uTWlEPTB;MD6wNlYh\|ryP	M1voSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
CCRF-CEM	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm1R\|RlOTBizszN	NWfLS5U{QTZiaB?=		MXvJR\|UxRTBwMEm0JO69VQ>?	M3iydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
Kasumi-1	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWKxNEDPxE1?	NULGToZtQTZiaB?=		NFK3Xm5KSzVyPUCuNVA{KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODFyOEOzPEc,OjBzMEizN\|g9N2F-
Karpas-299	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWKy[FdsOTBizszN	MX65OkBp		MkPnTWM2OD1yLkCzPEDPxE1?	NXfRV4FsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxNFg{OzhpPkKwNVA5OzN6PD;hQi=>
Ramos-RA1	M2\odGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NESxSnAyOCEQvF2=	NHu2PGk6PiCq		MmHBTWM2OD1yLkGyO{DPxE1?	M3\4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUC4N\|M5Lz5{MEGwPFM{QDxxYU6=
GSS	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEnJe2Q4OiCqcoO=		M3LpWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR2PTJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wN\|kh\|ryPLh?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
LU99A	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1rDRlczKGi{cx?=		MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyXOUnBJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wOlIh\|ryPLh?=	NGfjc3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
HL60	M4njZWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFHMOoM4OiCqcoO=		MoPSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTE[wJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCZU2S4JIF{e2G7LDDJR\|UxKD1iMD6wO\|Qh\|ryPLh?=	MoC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
LC2/ad	NXvPNXdpSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVP5VFhZPzJiaILz		NX3uUI1[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMR\|Iw[WRiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjB5NzFOwG0v	M{nQOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1OlE4Lz5{NU[yOVYyPzxxYU6=
MKN45	NYq3bIdqSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWL0UW9lPzJiaILz		NFGxd45CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4xQTNizszNMi=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
HCT116	MoTXRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1rMbFczKGi{cx?=		NXH3[pQ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjB7NTFOwG0v	M4raUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1OlE4Lz5{NU[yOVYyPzxxYU6=
Lu116	MlfuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmXKO\|IhcHK\|		M1q5PWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTIWxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGfTWFgh[XO\|YYmsJGlEPTBiPTCwMlA6PyEQvF2u	NF3MU5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVYyPyd-MkW2NlU3OTd:L3G+
NCI-H358	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlnCO\|IhcHK\|		MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IN\|U5KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3Q5KGG\|c3H5MEBKSzVyIE2gNE4yKM7:TT6=	MkfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkW2NVcoRjJ3NkK1OlE4RC:jPh?=
MIAPaCa2	NFzNWGVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M17nR\|czKGi{cx?=		M{f1O2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBVIFE[TJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHdUXDhiYYPzZZktKEmFNUCgQUAxNjF\|IN88UU4>	NW\HTmtvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
PC14	NYDFOZF5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3HZZlczKGi{cx?=		NGjIUpZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDNVQh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGfTWFgh[XO\|YYmsJGlEPTBiPTCwMlE4KM7:TT6=	NXXMSnhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NlU3OTdpPkK1OlI2PjF5PD;hQi=>
HT-29	NGfKW5JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NX;PVIlUPzJiaILz		NXe0d2V5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVQCCjc4PhfUwhUUN3MDC9JFAvOzNizszNMi=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
HCT15	MlvNRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{DhXFczKGi{cx?=		MmXKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxOUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUPEBie3OjeTygTWM2OCB;IECuO\|Qh\|ryPLh?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ{NU[xO{c,OjV4MkW2NVc9N2F-
Sf9	MX7GeY5kfGmxbjDhd5NigQ>?				NGjSRYFEd22yZYTpeIl3\SCrbnjpZol1cW:wIH;mJJJm[2:vYnnuZY51KG2xdYPlJIF2em:{YTDrbY5ie2ViQTDlfJBz\XO\|ZXSgbY4hcW6\|ZXP0JHNnQSClZXzsd{BqdiCycnXz[Y5k\SCxZjDBWHAtKEurIE2gNE4xODB\|IN88UU4>	NUnX[4FTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNFE2PjRpPkK2NVAyPTZ2PD;hQi=>
Sf9	MU\GeY5kfGmxbjDhd5NigQ>?				MkfvTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDtc5V{\SCjdYLvdoEhc2mwYYPlJGEh\XiycnXzd4VlKGmwIHnud4VkfCCVZkmgZ4VtdHNidYPpcoch[mmxdHnuMWdNWlKDU1zHJIF{KHO3YoP0doF1\SCrbjDwdoV{\W6lZTDv[kBc\2GvbXGtN\|NRZUGWUDygTWM2OCB;IECuNFAyKM7:TT6=	M3n1R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUCxOVY1Lz5{NkGwNVU3PDxxYU6=
HCT116	NYe4Z5k1TnWwY4Tpc44h[XO\|YYm=				NXPIc4w5UW6qaXLpeIlwdiCxZjDheZJwemFia3nuZZNmKEFiYYX0c5Bpd3OyaH;yfYxifGmxbjDheEBVOjh6IHnuJIh2dWGwIFjDWFEyPiClZXzsd{BjgSCrbX31co9ndHWxcnXzZ4Vv[2ViYX7hcJl{cXNuIFnDOVAhRSByLkCwO{DPxE1w	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFyMUW2OEc,OjZzMEG1OlQ9N2F-
HCT116	NWDXOHRwS3m2b4TvfIlkcXS7IHHzd4F6				MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[nliQoLkWUBqdmOxcoDvdoF1cW:wIHHzd4F6NCCJSUWwJF0hOC5yMzFOwG0v	NGT5eZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGwNVU3PCd-Mk[xNFE2PjR:L3G+
HCT116	M4HYS2Z2dmO2aX;uJIF{e2G7				MoLXTY5pcWKrdHnvckBw\iCjdYLvdoEhc2mwYYPlJGIhcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaHnzeI9v\SCKMzDwbI9{eGixconsZZRqd25iYomgbY1ufW6xZnz1c5Jme2OnbnPlJIFv[Wy7c3nzMEBKSzVyIE2gNU42KM7:TT6=	NGjscGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGwNVU3PCd-Mk[xNFE2PjR:L3G+
BL21 (DE3) Rosetta	NF3vfHNHfW6ldHnvckBie3OjeR?=		M3SxeVMxKG2rboO=		NFO0UGVKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgbJVu[W5iQYXyc5JiKEFia3nuZZNmKChzMkKgeI8hPDBicnXzbYR2\XNrIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{khWm:\|ZYT0ZUBk\WyuczD1d4lv\yCkaX;0bY56dGG2ZXSgV3RMOiC\|dXLzeJJifGViaX7jeYJifGWmIH\vdkA{OCCvaX7zJIJ6KEiWUl[gZZN{[XluIFnDOVAhRSByLkCwNFA1KM7:TT6=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7MUGzN{c,Ojd\|OUGxN\|M9N2F-
HeLa Kyoto	NIrwToJHfW6ldHnvckBie3OjeR?=		M17lWFIxKGi{cx?=		MnviTY5pcWKrdHnvckBw\iCDdYLvdoEhSiCtaX7hd4UhcW5iaIXtZY4hUGWOYTDLfY91dyClZXzsd{Bie3Onc4Pl[EBieyCnZn\lZ5Qhd25iZHnzeJJq[nW2aX;uJI9nKHCqc4Doc{1pcXO2b37lJGg{KHOnckGwJIxmfmWuIHnuZ5Vj[XSnZDDmc5IhOjBiaILzMEBKSzVyIE2gNE4xODF3IN88UU4>	M{jLbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{mxNVM{Lz5{N{O5NVE{OzxxYU6=
HeLa Kyoto	NWXnNINQTnWwY4Tpc44h[XO\|YYm=		NX7VUJZbOjBiaILz		NY\ucJgyUW6qaXLpeIlwdiCxZjDBeZJwemFiQTDrbY5ie2ViYYX0c5Bpd3OyaH;yfYxifGmxbjDheEBVcHJ{OEigbY4hcHWvYX6gTIVN[SCNeX;0c{Bk\WyuczDpcoN2[mG2ZXSg[o9zKDJyIHjyd{whUUN3MDC9JFAvODB4NzFOwG0v	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7MUGzN{c,Ojd\|OUGxN\|M9N2F-
multiple myeloma	MXHGeY5kfGmxbjDhd5NigQ>?				M4XITXN2eHC{ZYPzbY9vKG:oIHPlcIwhdWm2b4Ppd{BqdiCqdX3hckBufWy2aYDs[UBugWWub33hJINmdGy\|LDDJR\|UxKD1iMD6wNFMh\|ryPLh?=	M3v1N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUG4NFk3Lz5{OEmxPFA6PjxxYU6=
Calu6	M1zIVWFvfGm2dX3vdkBie3OjeR?=	MYKyNEBu\y:tZx?=	MU[yNUBl[Xm\|		NIfpXWJCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDZYx2PiClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDtc5V{\SCjc4Pld5Nm\CCjczD0eY1weiCpcn;3eIghcW6qaXLpeIlwdiCjdDCyNEBu\y:tZzygdI8h[mmmIHHkcYlvcXO2ZYLl[EBnd3JiMkGg[IF6ew>?	NET4bog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGwNVU3PCd-Mk[xNFE2PjR:L3G+
HeLa Kyoto	NYHUUYFvTnWwY4Tpc44h[XO\|YYm=	MmfvNE4zPSC3TR?=	MV6yNEBpenN?		MoG0TY5pcWKrdHnvckBw\iCDdYLvdoEhSSCtaX7hd4UhdG:lYXzpfoF1cW:wIHH0JJNxcW6mbHWgcYlkem:2dXL1cIV{KGmwIHj1cYFvKEinTHGgT5lwfG9iY3XscJMh[XRiMD6yOUB2VSCrbnP1ZoF1\WRiZn;yJFIxKGi{cx?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7MUGzN{c,Ojd\|OUGxN\|M9N2F-
MDA-MB-231	NXrhbGhQTnWwY4Tpc44h[XO\|YYm=	NUS4PHVpOSC3TR?=	M3jOZVQ5KGi{cx?=		NEmzU5pKdmS3Y4Tpc44hd2ZiY3jyc41we2:vZTDhcIlodm2nboSg[IVn\WO2czDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiaX3teY5w\my3b4Lld4NmdmOnIHHzd4F6	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN3OEG0O{c,Ojl\|NUixOFc9N2F-
MDA-MB-231	MoHhSpVv[3Srb36gZZN{[Xl?	M4r5fFEhfU1?	NEnVWVA1QCCqcoO=		NIftSVhKdmS3Y4Tpc44hd2ZiYXLldpJidnRic4DpcoRt\SCob4LtZZRqd25id3n0bEB1emmyb3zhdkBidmRidHX0doFxd2yjcjDvZ4N2enKnbnPlJIlvKGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOSC3TTDh[pRmeiB2ODDodpMh[nliRFHQTUB{fGGrbnnu[{Bj[XOnZDDpcY12dm:obIXvdoV{[2WwY3WgZZN{[Xl?	M{PzNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{W4NVQ4Lz5{OUO1PFE1PzxxYU6=
MDA-MB-231	MWnGeY5kfGmxbjDhd5NigQ>?	NETSXGkxNjVidV2=	MW[0PEBpenN?		MUjJcohq[mm2aX;uJI9nKGGucHjhMZR2[nWuaX6gbY4hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{Bi[m:uaYPocYVvfCCxZjDy[Yd2dGG{IHzvZ4F1cW:wIH;mJJBzd3SnaX6gZZQhOC53IIXNJIFnfGW{IES4JIhzeyCkeTDERXBKKHO2YXnubY5oKGKjc3XkJIludXWwb3\seY9z\XOlZX7j[UBie3OjeR?=	M2PT[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{W4NVQ4Lz5{OUO1PFE1PzxxYU6=
MDA-MB-231	M4[4PWZ2dmO2aX;uJIF{e2G7	M4TNVFAvPSC3TR?=	NXT1XpppPDhiaILz		M{nsfGlvcGmkaYTpc44hd2ZiQWXST2EhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCjYn;sbZNpdWWwdDDv[kBz\We3bHHyJIxw[2G2aX;uJI9nKHC{b4TlbY4h[XRiMD61JJVOKGGodHXyJFQ5KGi{czDifUBFSVCLIIP0ZYlvcW6pIHLhd4VlKGmvbYXuc4ZtfW:{ZYPj[Y5k\SCjc4PhfS=>	MlLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|NUixOFcoRjJ7M{W4NVQ4RC:jPh?=
TC32	NFTFdm1yUFSVIHHzd4F6				NVm3[I17eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGTDN\|Ih[2WubIO=	NIL5fGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NUf3N4hqeUiWUzDhd5NigQ>?				Mlr2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	M{jsdZFJXFNiYYPzZZk>				NFHwcpVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	M2TyflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MYDxTHRUKGG\|c3H5				NIPFfZVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	MlrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MnvhdWhVWyCjc4PhfS=>				MmG1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NVPSWIVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	NGfwbG1yUFSVIHHzd4F6				NFTxOVZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSi2HQnOxJINmdGy\|	M4DJeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	M2POZZFJXFNiYYPzZZk>				NEX2RWxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	NFvzVVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
U-2 OS	Mk\6dWhVWyCjc4PhfS=>				MofLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{	M4m3W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	MojWdWhVWyCjc4PhfS=>				MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NF3o[lU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MljodWhVWyCjc4PhfS=>				NH\PdmFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	M2[2U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	MlLydWhVWyCjc4PhfS=>				MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	M37s[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MUnxTHRUKGG\|c3H5				NULLe2ZteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	NVzROWZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NVfGRndMeUiWUzDhd5NigQ>?				MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	NW\KbFV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MWTxTHRUKGG\|c3H5				MknUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	MmflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	NYPrbmxJeUiWUzDhd5NigQ>?				M1ftZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	M2C5NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	M4nZbpFJXFNiYYPzZZk>				NITIVW9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:\|LUKgZ4VtdHN?	Mn3GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AURKA(T288) / p-EIF4E(S209) / c-Myc; PubMed: 28073841 Clin Cancer Res Inhibition of AURKA with alisertib downregulated p-EIF4E (S209) and c-MYC protein levels as assayed by Western blotting. phospho-Aurora A / Aurora B; PubMed: 22863010 Cell MLN8237differentially inhibited phosphorylation of Aurora kinases. CMK cells were incubated with 0.1 µM paclitaxel for 18 hr, then DMSO or MLN8237 was added and incubated for 2 hr. The degree of phosphorylation of the Aurora kinases in each sample was determined by Western blot. H3S10P / H3K27me2 / H3K27me3 / H3K9me2 / H3AcK / H4K16Ac; PubMed: 29477140 Mol Cells THP-1 cells were treated with alisertib or DMSO for 48 h. The levels of histone modifications were detected by western blot analysis with the indicated antibodies. H3 was used as a loading control.	28073841 22863010 29477140
Growth inhibition assay	Cell viability; PubMed: 25632225 Drug Des Devel Ther PANC-1 and BxPC-3 cells were treated with ALS at concentrations ranging from 0.1 μM to 50 μM for 24 hours. The viability of PANC-1 and BxPC-3 cells determined by MTT assay. ALS, alisertib.	25632225
Immunofluorescence	acetylated α-tubulin / γ-tubulin; PubMed: 29401581 FASEB J Representative immunofluorescence (IF) image and graph in human PKD1-mutant WT9-7, WT9-12 cells or hTERT-RPE1 (RPE1) cells after 2 hours treatment with vehicle, ganetespib , or alisertib to inhibit AURKA, or combination of alisertib and ganetespib. acetylated α-tubulin (red); γ-tubulin (green); DAPI (blue). Scale bars, 5 μm. E-cadherin / β-catenin / vimentin / p-SMAD5; PubMed: 23334326 Oncogene Immunofluorescence analysis of CD24 (-/low) cells treated with1 μM MLN8237 for 48 and 72 h showing reversion of EMT. E-cadherin and p-SMAD5 were labeled in red, β-catenin and vimentin were labeled in green, and DNA was labeled in blue with Hoechst dye. Centrin-2 / tubulin; PubMed: 30899434 Oncotarget Following inhibition of Aurora A kinase activity with 100 nM alisertib, cells with two or excess centrosomes similarly exhibit disorganized mitotic spindles. Cells with extra centrosomes are efficiently clustered into bipolar spindles prior to anaphase onset while those with supernumerary centrosomes undergo multipolar mitoses. Centrin-2, a marker of centrioles is shown in green, tubulin in red, and chromatin in blue. AurA inhibitor: alisertib. phospho-Aurora A(T288); PubMed: 20382844 Blood MM1.S cells were treated with DMSO or MLN8237 (0.5μM) for 24 hours and then stained with anti-phospho (Thr288)-Aurora-A kinase antibody (red), αtubulin (green), and DNA (blue). Overlapping localization is shown in the merged images. Arrow indicates Aurora-A autophosphorylation on Thr288 in the centrosome (original magnification ×40). Magnified single mitotic cell image is shown in the right panel.	29401581 23334326 30899434 20382844

In vivo

MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Aurora A radioactive Flashplate enzyme assay: Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl₂, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-³³P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:^[2]	- Collapse Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266 Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 24, 48, and 72 hours Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using ³[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells Dosages: ~30 mg/kg/day Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	27 mg/mL (52.03 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+30% PEG300+5%Tween-80+ddH2O For best results, use promptly after mixing.	6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Alisertib (MLN8237) SDF

Molecular Weight	518.92
Formula	C₂₇H₂₀ClFN₄O₄
CAS No.	1028486-01-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	COC1=C(C(=CC=C1)F)C2=NCC3=CN=C(N=C3C4=C2C=C(C=C4)Cl)NC5=CC(=C(C=C5)C(=O)O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04479306	Recruiting	Drug: Alisertib\|Drug: Osimertinib\|Drug: Sapanisertib	EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma\|Recurrent Lung Non-Small Cell Carcinoma\|Stage IIIB Lung Cancer AJCC v8\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	June 18 2020	Phase 1
NCT02812056	Withdrawn	Drug: Alisertib\|Drug: TAK-228	Malignant Neoplasms of Digestive Organs\|Malignant Neoplasms of Female Genital Organs\|Malignant Neoplasms of Lip Oral Cavity and Pharynx\|Malignant Neoplasms of Male Genital Organs	M.D. Anderson Cancer Center\|Millennium Pharmaceuticals Inc.	September 2016	Phase 1
NCT02719691	Active not recruiting	Drug: Alisertib\|Drug: MLN0128	Metastatic Breast Cancer\|Solid Tumors	University of Colorado Denver	May 13 2016	Phase 1
NCT02367352	Terminated	Drug: Alisertib\|Drug: Paclitaxel	Advanced Solid Tumors\|Ovarian Cancer\|Small Cell Lung Cancer	Millennium Pharmaceuticals Inc.\|Takeda	March 19 2015	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the suggested formulation of this compound for mouse injection(i.p.)?
Answer:
It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitor

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitor

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

VX-680 (Tozasertib, MK-0457) : Phase II for Advanced Non-Small Cell Lung Cancer (NSCLC).
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007) is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 is associated with an increase in p38 activation and may induce p38-dependent apoptosis/senescence. ML141 also protects neuroblastoma cells from metformin-induced apoptosis.
Barasertib (AZD1152-HQPA)

Barasertib (AZD1152-HQPA, AZD2811) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Tozasertib (VX-680, MK-0457)

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. The only exceptions are Fms-related tyrosine kinase-3 (FLT-3) and BCR-ABL tyrosine kinase, which are inhibited by the Tozasertib with both Ki of 30 nM. Tozasertib induces apoptosis and autophagy. Phase 2.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Danusertib induces apoptosis, cell cycle arrest, and autophagy. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. MK-5108 (VX-689) induces autophagy. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I (TC-S 7010) is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B. Aurora A Inhibitor I (TC-S 7010) triggers apoptosis through the ROS-mediated UPR signaling pathway.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Alisertib (MLN8237)